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Motexafin Gadolinium (MGd) is active as a single agent in 
advanced non-small-cell lung cancer (NSCLC) patients who failed 
platinum-based chemotherapy: preliminary results of a phase II 
trial
Natale, Ronald B.1 Nicholas, Garth2 Greco, Frank3 Govindan, 
Ramaswamy4,8 Chabot, Pierre5 Pandya, Kishan6 Eubank, Lane7 
Renschler, Markus F.7 
1 Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA, USA 2 Ot-
tawa Hospital Regional Cancer Center, Ottawa, ON, Canada 3 Sarah 
Cannon Cancer Center, Nashville, TN, USA 4 Washington University 
School of Medicine, St.Louis, MO, USA 5 Hospital Maisonneuve-Rose-
mont, Montreal, QC, Canada 6 University of Rochester, Rochester, NY, 
USA 7 Pharmacyclics, Sunnyvale, CA, USA 8 Siteman Cancer Center, 
St.Louis, MO, USA 
Background: Motexaﬁn gadolinium (MGd) is a tumor-selective 
antineoplastic agent that disrupts redox dependent pathways by target-
ing oxidative stress-related proteins such as thioredoxin reductase 
(TRX). TRX often is overexpressed in NSCLC and is associated with 
a poor prognosis. Inhibition of TRX reverses tumor phenotype in lung 
carcinoma cells in vitro and in vivo. This randomized 2-stage phase II 
trial investigated tumor response and survival with 2 regimens of single 
agent MGd for the 2nd line treatment of advanced NSCLC.
Methods: Patients with locally advanced or metastatic NSCLC ± brain 
metastases, ECOG PS 0-1, who had received one prior platinum-based 
chemotherapy regimen ± kinase inhibitor were randomized to intrave-
nous MGd (10 mg/kg/week - Group A) or MGd (15 mg/kg/q 3 weeks 
- Group B) given in 21 day cycles. The sample size was 30 per arm in 
stage 1, and 24 per arm in stage 2. Response was evaluated by RECIST 
every 6 weeks. 
Results: 56 evaluable patients, median age of 62 years (range 41-85), 
with locally advanced (16%) or metastatic (84%) adenocarcinoma 
(46%), squamous cell carcinoma (16%), large cell carcinoma (9%), 
bronchoalveolar carcinoma (4%) or other NSCLC (25%) were random-
ized to group A (N=26) or group B (N=30). 38% had not responded to 
ﬁrst line chemotherapy. MGd treatment was well tolerated, with 1-12 
cycles (median 2, mean 3) administered. The most common MGd re-
lated grade 3+ adverse events were hypophosphatemia (17.9%), fatigue 
(12.5%), ﬁnger blisters (5.4%) and rash (5.4%). 53 patients were evalu-
able for response, with a response rate of 5.7% (3 PR, 2 in Group A, 1 
in Group B), and 37.7% stable disease. Median time to progression was 
12 weeks with 41% free from progression > 1 year. Median survival 
of 56 evaluable patients was 10.2 months (95% CI: 6.7 months - not 
reached), with 1-year survival of 44%. Median survival for Group A is 
not reached at > 14 months, and 9.2 months for Group B.
Conclusions: MGd appears active as a single agent for second line 
treatment of NSCLC patients with advanced or metastatic NSCLC who 
have failed prior platinum-based chemotherapy, with a response rate 
comparable to other approved agents, promising survival, and a favor-
able safety proﬁle. The trial has met the criteria for continuation into 
stage 2 for each treatment group. 
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Pharmacokinetics of gefitinib predicts the antitumor activity for 
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Background: Little is known about the relationship between the phar-
macokinetics and efﬁcacy of geﬁtinib. 
Methods: Plasma trough levels of geﬁtinib were measured on days 0, 
3 (D3), and 8 (D8) by HPLC in advanced NSCLC patients treated with 
geﬁtinib 250 mg daily. Eligibility criteria included: performance status 
(PS) ≤ 3, age ≤ 80, stage IIIB-IV, and written informed consent. 
Results: Fifty patients were enrolled, and 44 patients were assessable. 
The median [25%-75%] values of D3 and D8 was 662 [440-937] and 
1064 [782-1405] ng/ml, respectively. D8/D3 rate was categorized by 
1.587 of the median value. In 44 patients, the median time to progres-
sion (TTP) was 83 days, and the median overall survival (OS) was 224 
days. The differences in TTP were compared by Kaplan-Meier method 
and log-rank test: D8/D3 (high D8/D3, median 209 days vs. low D8/
D3, 43 days; P = 0.0229), smoking (never-smokers, 224 days vs smok-
ers, 32 days; P = 0.0467), and histology (adenocarcinoma, 97 days vs. 
non-adenocarcinoma, 27 days; P = 0.0096). Sex, age, PS, previous 
treatments, and the use of antacids were not signiﬁcant. Multivariate 
analysis showed that TTP was associated with D8/D3 (hazard rate, 
95%CI; 0.458, 0.234-0.898) and smoking (2.005, 1.030-3.903). Never-
smokers with high D8/D3 showed the best TTP, and smokers with low 
D8/D3 showed the worst TTP. Never-smokers with low D8/D3 and 
smokers with high D8/D3 showed similar TTP curves. In contrast, OS 
was associated with smoking (hazard rate, 95%CI; 3.182, 1.506-6.724), 
but not D8/D3. 
Conclusions: High D8/D3 was independently associated with better 
TTP in geﬁtinib-treated NSCLC patients. Our ﬁndings suggest that 
pharmacokinetics of geﬁtinib may be involved in its anti-tumor activity.
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Background: Geﬁtinib (ZD1839, IressaTM), one of the oral epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors has favorable 
response in subgroups of patients, especially in Asian population. It 
also has been reported that the IRESSA Survival Evaluation in Lung 
Cancer (ISEL) phase III trial showed signiﬁcantly longer survival in the 
geﬁtinib group than the placebo group for never-smoker and patients of 
Asian origin. Geﬁtinib was available in Korea since 2002, therefore in 
this study we compared the overall survival in patients with advanced 
non-small cell lung cancer (NSCLC) between pre-geﬁtinib and post-
geﬁtinib eras. 
Methods: Between January 1999 and December 2005, a total of 805 
patients with advanced/metastatic or recurrent NSCLC who were treat-
